Cardinal Health Inc. closed 4.35% short of its 52-week high of $132.84, which the company achieved on January 30th.

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks Cardinal’s earnings track record is “undeniable and ...

Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to ...

Cardinal Health CAH reported better-than-expected second-quarter financial results on Thursday. Cardinal Health posted adjusted earnings of $1.93 per share, beating market estimates of $1.76 per ...

Dublin City Schools is officially withdrawing from an agreement with Cardinal Health to purchase a vacant office building, Superintendent John Marschhausen told board members at a meeting Monday ...

Mizuho Securities analyst Steven Valiquette has reiterated their bullish stance on CAH stock, giving a Buy rating yesterday. Steven Valiquette has given his Buy rating due to a combination of ...

DUBLIN, Ohio, Feb. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved a quarterly dividend of $0.5056 per share out of the Company's capital ...

Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient ...

Non-GAAP net earnings attributable to Cardinal Health, Inc.: net earnings attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) state opioid assessment related to prior ...

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals ...

The desire to safely provide care for patients at home is creating a ripe opportunity for companies like Masimo, Cardinal Health, Medline Industries and McKesson, despite some uncertainty.